0001599298-20-000026.txt : 20200710 0001599298-20-000026.hdr.sgml : 20200710 20200710083922 ACCESSION NUMBER: 0001599298-20-000026 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200710 FILED AS OF DATE: 20200710 DATE AS OF CHANGE: 20200710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics plc CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 201021924 BUSINESS ADDRESS: STREET 1: 136A EASTERN AVENUE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4SB BUSINESS PHONE: 44-123-544-3939 MAIL ADDRESS: STREET 1: 136A EASTERN AVENUE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4SB FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 6-K 1 july20206-kcoverpageop.htm 6-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
FORM 6-K  
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2020
Commission File Number 001-36866
 

 SUMMIT THERAPEUTICS PLC
(Translation of registrant’s name into English)
 
 
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F  x            FORM 40-F  ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

















On July 9, 2020, the Board of Directors of Summit Therapeutics plc (the “Company”) appointed Jos Houbiers as Chief Medical Officer of the Company. Dr. Houbiers will receive an annual salary of £254,993 in his capacity as Chief Medical Officer.

In connection with his appointment, Dr. Houbiers was granted options to buy 320,000 American Depositary Shares (“ADSs”) in the aggregate. Of the grant to Dr. Houbiers, 300,000 of the options to buy ADSs have an exercise price of $3.31 per ADS, and 20,000 of the options to buy ADSs have an exercise price of $3.17 per ADS. The exercise prices of the options to buy ADSs represent the closing prices of the Company’s ADSs listed on the Nasdaq Global Market on July 8, 2020 and July 9, 2020 respectively, the dates of each applicable grant.

In addition, the Company granted options to buy ADSs to Ventzislav Stefanov. Dr. Stefanov was granted options to buy 200,000 ADSs in the aggregate, with the grant having an exercise price of $3.31 per ADS. The exercise price of the options to buy ADSs represents the closing price of the Company’s ADSs listed on the Nasdaq Global Market on July 8, 2020, the date of the grant.

The grants to Dr. Houbiers and Dr. Stefanov shall vest in four equal annual installments with the first such installment occurring on the one year anniversary of the applicable grant date, subject in each case to the satisfaction of certain performance targets to be established by the Company’s Board of Directors.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC
Date: July 9, 2020By:/s/ Robert Duggan
Robert Duggan
Chief Executive Officer